A Phase 1/2 interventional study of Opt-IVF and control in Ivf, sponsored by Urmila DIwekar. Recruiting at 1 site in United States. Open to female participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Urmila DIwekar · Phase 1/2, Interventional, and Treatment
A clinical trial will determine the effectiveness of the Opt-IVF decision-support tool in generating personalized, optimal drug-dosage profiles for each patient in the United States.
This will be a two-arm randomized clinical trial involving more than 100 patients; one arm will undergo superovulation using dosages predicted by the decision-support tool, while the other will receive the current standard treatment. The research question is whether outcomes of patient dosage treatment using Opt-IVF are better or similar to the current practice. We will compare the outcomes of the two groups of patients in terms of the numbers and percentage of mature follicles retrieved at the end of each cycle, total FSH and HMG dosages used, and the number of required testing days for that cycle, total number of M2s, Number of embryos, Number of Grade A embryos, and Number of Grade A blastocysts.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's planned enrollment of 100 is below the median of 120 across 1,698 interventional studies indexed under Infertility.
Browse Infertility studies →Urmila DIwekar is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Normal Responders
Exclusion Criteria:
Opt-IVF 1.0 arm will receive personalized total-gonadotropin optimization predicted dosage per day
Device: Opt-IVF
This standard-care arm will receive physician-directed dosing
Other: control
Opt-IVF predicted dosage for IVF
Doctor prescribed dosage
Total Gonadotropin dosage
Total Dosage
Time frame: 11 days
M2 Oocytes
M2 Oocytes
Time frame: 13 days
Total Embryos
Number of Embryos
Time frame: 15 days
Grade A Blastocysts
No. of Grade A blastocysts
Time frame: 20 days
Plan to share: Yes — by contacting the PI.
Supporting information: Study protocol, Sap, Icf, Csr
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Long Qt Syndrome 3
Urmila DIwekar